Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice

被引:122
|
作者
Ostos, MA
Conconi, M
Vergnes, L
Baroukh, N
Ribalta, J
Girona, J
Caillaud, JM
Ochoa, A
Zakin, MM
机构
[1] Inst Pasteur, Unite Express Genes Eucaryotes, F-75724 Paris 15, France
[2] Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, Paris, France
[3] Univ Rovira & Virgili, Unitat Recerca Lipids & Arteriosclerosis, Reus, Spain
[4] Rhone Poulenc Rorer, Vitry Sur Seine, France
关键词
antioxidants; apolipoprotein A-IV; atherosclerosis; transgenic mice;
D O I
10.1161/01.ATV.21.6.1023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mice expressing human apolipoprotein A-IV (apoA-IV) mainly in the intestine were obtained in an apolipoprotein E-deficient (apoE(o)) background (apoA-IV/E-o mice). Quantification of aortic lesions and plasma lipid determination showed that compared with their control apoE(o) counterparts, the apoA-IVIE, mice are protected against atherosclerosis without an increase in HDL cholesterol, Because oxidized lipoproteins play an important role in atherogenesis, we tested whether the protection observed in these animals is accompanied by an in vivo reduction of the oxidation parameters. The lag time in the formation of conjugated dienes during copper-mediated oxidation, the aggregation state of LDL, and the presence of anti-oxidized LDL antibodies were measured. The presence of oxidized proteins in tissues and the presence of oxidation-specific epitopes in heart sections of atherosclerotic lesions were also analyzed. Except for lag time, the results showed that the oxidation parameters were reduced in the apoA-IV/E-o mice compared with the apoE(o) mice. This suggests that human apoA-IV acts in vivo as an antioxidant, In addition, human apoA-IV accumulation was detected in the atherosclerotic lesions of apoA-IV/E-o mice, suggesting that apoA-IV may inhibit oxidative damage to local tissues, thus decreasing the progression of atherosclerosis.
引用
收藏
页码:1023 / 1028
页数:6
相关论文
共 50 条
  • [1] Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice
    Hayek, T
    Attias, J
    Smith, J
    Breslow, JL
    Keidar, S
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (04) : 540 - 544
  • [2] Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice
    Chapman, S
    Sabo, T
    Roses, AD
    Michaelson, DM
    NEUROSCIENCE, 2000, 97 (03) : 419 - 424
  • [3] Reversal of neuronal deficits of apolipoprotein E-deficient mice by human apolipoprotein E transgenes
    Chapman, S
    Sabo, T
    Michaelson, DM
    NEUROSCIENCE LETTERS, 1999, : S11 - S11
  • [4] Development of Apolipoprotein E-Deficient Mice
    Maeda, Nobuyo
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (09) : 1957 - 1962
  • [5] Cardiovascular effects of uremia in apolipoprotein E-deficient mice
    Bro, Susanne
    DANISH MEDICAL BULLETIN, 2009, 56 (04) : 177 - 192
  • [6] Role of angiotensin IV on endothelial function in apolipoprotein E-deficient mice
    Vinh, A
    Widdop, RE
    Gaspari, TA
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (07) : A47 - A47
  • [7] Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apolipoprotein E-deficient mice
    Shah, PK
    Nilsson, J
    Kaul, S
    Fishbein, MC
    Ageland, H
    Hamsten, A
    Johansson, J
    Karpe, F
    Cercek, B
    CIRCULATION, 1998, 97 (08) : 780 - 785
  • [8] Diet and Atherosclerosis in Apolipoprotein E-Deficient Mice
    Imaizumi, Katsumi
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2011, 75 (06) : 1023 - 1035
  • [9] Therapy of Atherosclerosis in Apolipoprotein E-Deficient Mice
    Wang, Min
    Yang, Hua
    Tan, Mengqun
    MOLECULAR THERAPY, 2014, 22 : S231 - S231
  • [10] Hyperphosphorylation of tau in apolipoprotein E-deficient mice
    Genis, I
    Michaelson, DM
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 251 - 256